FY2020 · ended Dec 31, 2020 · Revenue $0 · Filed Mar 30, 2022
Endra Life Sciences Inc. (NDRA) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. Free cash flow was -$5.2 million. As of Jun 30, 2026 it held $1.7 million in cash and investments and $429,274 in total debt.
Revenue
$0
Net income
$-7.03M
+38.9% vs prior year
Operating cash flow (TTM)
$-4.82M
+13.6% vs year-ago TTM
Free cash flow (TTM)
$-4.84M
+13.5% vs year-ago TTM
EPS
$-8.93
+84.3% vs prior year
Dividend per share
None
Shares outstanding
1.24M
+120.7% vs prior year
Net cash
$1.31M
as of Jun 30, 2026
Operating margin
-146080.5%
FY 2018
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- NDRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Ann Arbor, MI
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1681682
- Former names
- Endra Inc. (until Sep 21, 2016)
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$5.8M | -$10.8M | -$10.5M | -$13.2M | -$11.5M |
| Net income | -$7.0M | -$11.5M | -$10.1M | -$13.2M | -$11.2M |
| Diluted EPS | -$8.93 | -$56.94 | — | — | — |
| Operating cash flow | -$5.2M | -$7.4M | -$9.5M | -$12.8M | -$11.1M |
| Free cash flow | -$5.2M | -$7.4M | -$9.6M | -$13.0M | -$11.2M |
| Total assets | $3.9M | $4.5M | $6.8M | $9.3M | — |
| Total liabilities | $1.6M | $1.9M | $1.1M | $2.1M | — |
| Stockholders' equity | $2.3M | $2.6M | $5.7M | $7.2M | $10.8M |
| Cash and investments | $762,365 | — | — | $4.9M | $9.5M |
| Total debt | $492,352 | $584,419 | $394,403 | $518,147 | $650,477 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 17, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 9, 2026 | Jul 8, 2026 |
| 8-K |
Current report
Material agreement, Change in control, Regulation FD disclosure, Other events
|
Jun 26, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 25, 2026 | Jun 25, 2026 |
All 544 Endra Life Sciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.